# Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

> **NCT01111019** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 19 (actual)

## Conditions studied

- Hypochondroplasia

## Interventions

- **DRUG:** Recombinant human growth hormone (r-hGH)

## Key facts

- **NCT ID:** NCT01111019
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-21
- **Primary completion:** 2017-01-17
- **Final completion:** 2017-01-17
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01111019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01111019, "Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01111019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*